Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GILD

Gilead Sciences, Inc

Feb 14 • 04:00PM ET

104.08

Dollar change -1.88
Percentage change -1.77	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: ABBV BMY MRK PFE AMGN JNJ LLY VRTX REGN BIIB

| Held by: VTI VOO QQQ SPY IVV VTV XLV IBB COWZ VYM

Scroll to Statements

Index	NDX, S&P 500	P/E	280.61	EPS (ttm)	0.37	Insider Own	0.14%	Shs Outstand	1.25B	Perf Week	8.37%
Market Cap	129.71B	Forward P/E	12.68	EPS next Y	8.21	Insider Trans	-31.67%	Shs Float	1.24B	Perf Month	12.67%
Income	480.00M	PEG	12.05	EPS next Q	1.77	Inst Own	85.35%	Short Float	1.84%	Perf Quarter	10.31%
Sales	28.73B	P/S	4.51	EPS this Y	69.12%	Inst Trans	1.64%	Short Ratio	3.24	Perf Half Y	40.38%
Book/sh	15.45	P/B	6.74	EPS next Y	5.05%	ROA	0.79%	Short Interest	22.93M	Perf Year	41.55%
Cash/sh	8.02	P/C	12.98	EPS next 5Y	23.28%	ROE	2.28%	52W Range	62.07 - 106.43	Perf YTD	12.68%
Dividend Est.	3.22 (3.10%)	P/FCF	13.75	EPS past 5Y	-38.21%	ROI	1.20%	52W High	-2.21%	Beta	0.27
Dividend TTM	3.08 (2.96%)	Quick Ratio	1.20	Sales past 5Y	5.32%	Gross Margin	85.46%	52W Low	67.68%	ATR (14)	2.44
Dividend Ex-Date	Mar 14, 2025	Current Ratio	1.50	EPS Y/Y TTM	-91.54%	Oper. Margin	37.16%	RSI (14)	68.34	Volatility	2.41% 2.15%
Employees	18000	Debt/Eq	1.21	Sales Y/Y TTM	6.19%	Profit Margin	1.67%	Recom	1.91	Target Price	105.44
Option/Short	Yes / Yes	LT Debt/Eq	1.11	EPS Q/Q	24.81%	Payout	810.53%	Rel Volume	0.90	Prev Close	105.96
Sales Surprise	5.82%	EPS Surprise	9.35%	Sales Q/Q	6.50%	Earnings	Feb 11 AMC	Avg Volume	7.08M	Price	104.08
SMA20	7.42%	SMA50	10.83%	SMA200	27.98%	Trades		Volume	6,399,291	Change	-1.77%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-13-25	Upgrade	DZ Bank	Hold → Buy	$108
Jan-10-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$87 → $113
Dec-10-24	Resumed	BofA Securities	Buy	$109
Nov-15-24	Initiated	Wolfe Research	Outperform	$110
Nov-14-24	Initiated	Citigroup	Buy	$125
Nov-08-24	Downgrade	Maxim Group	Buy → Hold
Oct-21-24	Upgrade	Leerink Partners	Market Perform → Outperform	$74 → $96
Oct-17-24	Initiated	Bernstein	Outperform	$105
Oct-07-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$78 → $100
Jul-08-24	Upgrade	Raymond James	Mkt Perform → Outperform	$93
May-01-24	Reiterated	Maxim Group	Buy	$90 → $85
Apr-24-24	Upgrade	HSBC Securities	Reduce → Hold	$69
Feb-22-24	Downgrade	Truist	Buy → Hold	$91 → $82
Nov-09-23	Initiated	Deutsche Bank	Hold	$75
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy	$88 → $95
Sep-06-23	Initiated	HSBC Securities	Reduce	$71
Jul-24-23	Reiterated	Barclays	Equal Weight	$81 → $80
May-16-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$90 → $100
Apr-28-23	Resumed	Piper Sandler	Overweight	$105
Jan-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$87

Show Previous Ratings

Feb-13-25 09:50AM	Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Feb-12-25 04:36PM	S&P 500 Gains and Losses Today: CVS Stock Jumps as Pharmacy Segment Delivers Growth (Investopedia) +7.46%
04:18PM	Gilead Hits Buy Zone After Obliterating Fourth-Quarter Expectations (Investor's Business Daily)
01:49PM	Why Gilead Sciences (GILD) Stock Is Trading Up Today (StockStory)
12:21PM	Why Gilead Sciences Stock Is Jumping Today (Motley Fool)
10:53AM	Loading…
10:53AM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
10:44AM	Gilead Tops Buy Zone After Obliterating Fourth-Quarter Expectations (Investor's Business Daily)
09:40AM	Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
07:50AM	Q4 2024 Gilead Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
02:11AM	Gilead Sciences Inc (GILD) Q4 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ... (GuruFocus.com)
Feb-11-25 10:15PM	Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript (Motley Fool)
07:30PM	Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:10PM	Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates (Zacks)
05:05PM	Zillow, Gilead Sciences, Freshworks: After-Hours Earnings (Yahoo Finance Video)
04:31PM	Gilead Soars Into Buy Zone After Obliterating Fourth-Quarter Expectations (Investor's Business Daily)
04:14PM	Loading…
04:14PM	Gilead Sciences (NASDAQ:GILD) Delivers Strong Q4 Numbers (StockStory)
04:10PM	Gileads Profit View Tops Estimates After Strong End to Year (Bloomberg)
04:08PM	Gilead: Q4 Earnings Snapshot (Associated Press Finance)
04:08PM	Gilead provides upbeat 2025 forecast, shares rise 4% (Reuters)
04:08PM	Gilead Beats Earnings Estimates on Strong HIV Sales. The Stock Is Rising. (Barrons.com)
04:07PM	Gilead Outplays Veklury Downfall To Obliterate Forecasts. Will Shares Win Back Their Breakout? (Investor's Business Daily)
04:05PM	Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend (Business Wire)
04:02PM	Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
05:30AM	The Magnificent 7 Are So Last Year. Cash Cows Are the New Kings. (The Wall Street Journal)
Feb-10-25 07:00PM	Coca-Cola results, Powell testifies, SMCI update: What to Watch (Yahoo Finance Video)
08:04AM	Gilead Sciences (GILD) Q4 Earnings: What To Expect (StockStory)
Feb-09-25 02:30PM	3 Fabulous Dividend Stocks to Buy in February (Motley Fool)
Feb-08-25 08:30AM	These 2 Dividend Stocks Are Absolute Bargains Right Now (Motley Fool)
Feb-06-25 09:45AM	3 Top AI-Powered Biotech Stocks to Buy in February (Motley Fool)
09:15AM	Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
05:50PM	Loading…
Feb-05-25 05:50PM	Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
11:54AM	Is Gilead Sciences (GILD) the Best Wide Moat Stock to Invest In? (Insider Monkey)
Feb-04-25 10:00AM	Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-03-25 06:00PM	Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts (Zacks)
Jan-31-25 12:10PM	Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:47AM	Top 20 biopharma companies market caps rise 1.7% over 2024 amid policy (Pharmaceutical Technology)
07:09AM	Gilead Sciences, Inc. (GILD): AI Partnerships Enhancing Biopharmaceutical Advancements (Insider Monkey)
Jan-30-25 08:00AM	Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications (PR Newswire)
Jan-29-25 09:00AM	Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock (Zacks)
Jan-28-25 06:00PM	Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts (Zacks)
04:05PM	Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025 (Business Wire)
09:30AM	Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views? (Zacks)
Jan-24-25 04:31PM	Why Gilead Sciences (GILD) Is One of the Best Humane Stocks to Invest in Now? (Insider Monkey)
Jan-21-25 06:00PM	Why Gilead Sciences (GILD) Outpaced the Stock Market Today (Zacks)
05:30PM	Is Gilead Sciences (GILD) Among Billionaire Steve Cohens Top Stock Picks? (Insider Monkey)
Jan-17-25 03:25PM	House of the Week: A Riverfront Retreat in Southeastern Connecticut (The Wall Street Journal)
Jan-16-25 01:12PM	Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy? (Insider Monkey)
09:00AM	Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? (Zacks)
Jan-15-25 06:00PM	Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
03:44PM	Gilead Sciences, US government settle patent case over HIV prevention drugs (Reuters)
Jan-13-25 02:44PM	Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies (GuruFocus.com)
10:49AM	Gilead and LEO Pharma link on programmes for inflammatory conditions (Pharmaceutical Technology)
Jan-11-25 12:39PM	Gilead, LEO Pharma partner to develop programs for inflammatory diseases (Reuters)
11:00AM	Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases (Business Wire)
Jan-10-25 10:48AM	Morgan Stanley upgrades Gilead on HIV treatment growth (Investing.com)
05:30AM	Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. (The Wall Street Journal)
Jan-09-25 06:00PM	Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Jan-06-25 09:50AM	Heres Why TCW Relative Value Large Cap Fund Exited its Position in Gilead Sciences (GILD) (Insider Monkey)
07:48AM	Gilead Sciences, Inc. (GILD): A Bull Case Theory (Insider Monkey)
Jan-03-25 06:00PM	Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jan-02-25 10:52PM	Five Best: Novels in Letters (The Wall Street Journal)
Dec-31-24 05:28AM	Is Gilead Sciences, Inc. (GILD) the Best Dividend Stock of 2024? (Insider Monkey)
Dec-30-24 04:01PM	Is Gilead Sciences, Inc. (GILD) the Best Pharma Dividend Stock to Buy In 2024? (Insider Monkey)
Dec-29-24 03:00AM	Gilead Buys $20.1 Million of Assembly Biosciences Stock (Barrons.com)
Dec-27-24 05:54AM	Jim Cramer on Gilead Sciences, Inc. (GILD): I Dont Think The Business Is Worth As Much As The Stock Is Selling (Insider Monkey)
Dec-26-24 09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Dec-25-24 11:30AM	Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock (Benzinga)
Dec-23-24 03:25PM	Gilead Sciences Stock Today: Boost Your Return With This Covered Call Trade (Investor's Business Daily)
08:44AM	Gilead Sciences (GILD) Made Big Announcements in Q3 (Insider Monkey)
08:00AM	How To Invest: The Slow Saucer Base Can Produce Quick Returns (Investor's Business Daily)
Dec-20-24 04:05PM	Gilead Sciences to Present at Upcoming Investor Conference (Business Wire)
Dec-19-24 06:00PM	Gilead Sciences (GILD) Gains As Market Dips: What You Should Know (Zacks)
Dec-18-24 07:20AM	Gilead, Terray Therapeutics announce research collaboration (TipRanks)
06:58AM	Gilead and Terray link to develop small-molecule therapies (Pharmaceutical Technology)
Dec-17-24 08:30AM	U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer (Business Wire)
07:00AM	Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies (Business Wire)
Dec-16-24 12:00PM	Gilead (GILD) Upgraded to Buy: Here's Why (Zacks)
Dec-13-24 05:50PM	Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know (Zacks)
12:15PM	Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report (Benzinga)
06:37AM	Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis (Business Wire)
Dec-12-24 05:54PM	Gilead appoints Sanofi official Dietmar Berger as next chief medical officer (Reuters)
05:30PM	Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer (Business Wire)
01:13PM	Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing (Benzinga)
09:40AM	Is Gilead Sciences (GILD) Stock Undervalued Right Now? (Zacks)
09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:00AM	Looking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent Moneymakers (Benzinga)
Dec-09-24 05:45PM	Kite's Yescarta Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024 (Business Wire)
04:30PM	Longest Follow-Up Data Reported for Kite's Tecartus CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits (Business Wire)
04:22PM	Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. (Investor's Business Daily)
Dec-08-24 12:30PM	Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH (Business Wire)
Dec-05-24 04:00AM	Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying. (Barrons.com)
Dec-03-24 09:30AM	Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
07:00AM	Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target (Business Wire)
Dec-02-24 07:45AM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
Nov-28-24 05:05PM	Gilead announces PURPOSE 2 trial data published in NEJM (TipRanks)
09:00AM	Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know (Zacks)
07:07AM	Gileads twice-yearly lenacapavir shows promise in HIV prevention trial (Clinical Trials Arena)
Nov-27-24 05:00PM	Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results (Business Wire)
Nov-26-24 09:40AM	Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic (ACCESSWIRE)
07:43AM	Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech (Pharmaceutical Technology)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dickinson Andrew D	Chief Financial Officer	Feb 12 '25	Option Exercise	67.27	137,676	9,260,873	308,899	Feb 13 09:13 PM
Dickinson Andrew D	Chief Financial Officer	Feb 12 '25	Sale	102.22	137,676	14,073,241	171,223	Feb 13 09:13 PM
ANDREW DICKINSON	Officer	Feb 12 '25	Proposed Sale	102.22	137,676	14,073,241		Feb 12 04:03 PM
Dickinson Andrew D	Chief Financial Officer	Jan 31 '25	Option Exercise	67.52	142,180	9,600,576	273,053	Feb 03 06:09 PM
Dickinson Andrew D	Chief Financial Officer	Jan 31 '25	Sale	97.22	142,180	13,822,740	129,873	Feb 03 06:09 PM
ANDREW DICKINSON	Officer	Jan 31 '25	Proposed Sale	97.22	142,180	13,822,740		Jan 31 04:15 PM
MERDAD V PARSEY	Officer	Jan 31 '25	Proposed Sale	98.00	184,683	18,098,989		Jan 31 04:01 PM
Dickinson Andrew D	Chief Financial Officer	Jan 15 '25	Sale	91.35	2,500	228,375	129,873	Jan 16 03:31 PM
ANDREW DICKINSON	Officer	Jan 15 '25	Proposed Sale	91.35	2,500	228,375		Jan 15 04:18 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 19 '24	Buy	21.37	940,499	20,098,464	2,209,471	Dec 23 08:26 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 18 '24	Buy	1.04	1,759,978	1,830,377	9,105,451	Dec 19 04:19 PM
Dickinson Andrew D	Chief Financial Officer	Dec 16 '24	Sale	91.96	8,500	781,660	132,373	Dec 17 05:27 PM
ANDREW DICKINSON	Officer	Dec 16 '24	Proposed Sale	91.96	8,500	781,660		Dec 16 04:08 PM
Dickinson Andrew D	Chief Financial Officer	Nov 29 '24	Option Exercise	70.50	248,645	17,528,577	387,564	Dec 03 02:43 PM
Dickinson Andrew D	Chief Financial Officer	Nov 29 '24	Sale	92.76	248,645	23,065,271	138,919	Dec 03 02:43 PM
Parsey Merdad	Chief Medical Officer	Nov 27 '24	Option Exercise	62.44	145,413	9,079,689	245,012	Nov 29 08:10 PM
Parsey Merdad	Chief Medical Officer	Nov 27 '24	Sale	91.92	164,211	15,094,013	80,801	Nov 29 08:10 PM
ANDREW DICKINSON	Officer	Nov 29 '24	Proposed Sale	92.76	248,645	23,065,258		Nov 29 02:35 PM
Bluestone Jeffrey	Director	Nov 26 '24	Option Exercise	61.24	10,000	612,442	15,708	Nov 27 06:14 PM
Bluestone Jeffrey	Director	Nov 26 '24	Sale	91.39	6,788	620,356	8,920	Nov 27 06:14 PM
MERDAD V PARSEY	Officer	Nov 27 '24	Proposed Sale	91.92	164,211	15,094,008		Nov 27 04:15 PM
Bluestone Jeffrey	Director	Nov 26 '24	Proposed Sale	91.39	6,788	620,356		Nov 26 07:31 PM
Mercier Johanna	Chief Commercial Officer	Nov 06 '24	Sale	91.28	5,000	456,400	73,127	Nov 07 04:38 PM
Parsey Merdad	Chief Medical Officer	Nov 06 '24	Option Exercise	57.92	25,000	1,448,000	125,189	Nov 07 04:32 PM
Parsey Merdad	Chief Medical Officer	Nov 06 '24	Sale	91.50	25,590	2,341,485	99,599	Nov 07 04:32 PM
MERDAD V PARSEY	Officer	Nov 06 '24	Proposed Sale	91.50	25,590	2,341,485		Nov 06 04:19 PM
JOHANNA MERCIER	Officer	Nov 06 '24	Proposed Sale	91.28	5,000	456,400		Nov 06 04:07 PM
Parsey Merdad	Chief Medical Officer	Oct 01 '24	Sale	83.83	2,000	167,660	100,189	Oct 02 04:58 PM
MERDAD V PARSEY	Officer	Oct 01 '24	Proposed Sale	83.83	2,000	167,660		Oct 01 04:27 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Option Exercise	57.92	25,000	1,448,000	123,435	Sep 13 07:07 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Sale	84.50	21,246	1,795,287	102,189	Sep 13 07:07 PM
Mercier Johanna	Chief Commercial Officer	Sep 12 '24	Sale	83.78	29,357	2,459,577	78,127	Sep 13 05:08 PM
MERDAD V PARSEY	Officer	Sep 12 '24	Proposed Sale	84.50	21,246	1,795,287		Sep 12 04:45 PM
JOHANNA MERCIER	Officer	Sep 12 '24	Proposed Sale	83.78	29,357	2,459,577		Sep 12 04:43 PM
Mercier Johanna	Chief Commercial Officer	Aug 28 '24	Sale	78.03	9,513	742,299	105,466	Aug 29 03:23 PM
JOHANNA MERCIER	Officer	Aug 28 '24	Proposed Sale	78.03	9,513	742,299		Aug 28 04:18 PM
Mercier Johanna	Chief Commercial Officer	Aug 13 '24	Sale	73.98	5,490	406,150	114,979	Aug 14 02:23 PM
JOHANNA MERCIER	Officer	Aug 13 '24	Proposed Sale	73.98	5,490	406,150		Aug 13 04:27 PM
Parsey Merdad	Chief Medical Officer	Jul 01 '24	Sale	68.63	2,000	137,260	96,380	Jul 01 08:06 PM
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473	Apr 03 06:50 PM
Parsey Merdad	Chief Medical Officer	Apr 01 '24	Sale	72.96	2,000	145,920	96,304	Apr 02 06:38 PM
Parsey Merdad	Chief Medical Officer	Feb 29 '24	Sale	72.74	8,230	598,624	92,706	Feb 29 06:35 PM
Parsey Merdad	Chief Medical Officer	Feb 28 '24	Sale	73.18	2,000	146,360	100,936	Feb 29 06:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GILD

Gilead Sciences, Inc

Upgrade your FINVIZ experience